The World Health Organization (WHO), the European Society of Human Reproduction and Embryology (ESHRE), and 56 other global medical societies have agreed after 14 years to officially redefine polycystic ovary syndrome (PCOS) as polyendocrine metabolic ovarian syndrome (PMOS, Polyendocrine Metabolic Ovarian Syndrome), shifting its classification from an ovarian-limited disease to a systemic metabolic disorder, through the international journal The Lancet Confirmed. The previous name faced criticism for focusing solely on structural ovarian cysts, failing to represent the systemic metabolic abnormalities, such as insulin resistance and hyperandrogenism, experienced by the majority of patients. This renaming serves as a critical turning point, expanding the pathophysiological essence of the disease from a specific organ (ovary) to multi-organ endocrine disruption, thereby increasing early diagnosis rates.

Innovation in Diagnostic Systems and Treatment Paradigms to Address Unmet Needs

Despite affecting approximately 8-13% of women of reproductive age worldwide, about 70% of patients have experienced delayed diagnosis or misdiagnosis due to the existing terminology, missing the golden window for treatment. While maintaining the basic framework of the 2003 Rotterdam Criteria, this renaming officially mandates the necessity of metabolic screening in clinical settings, which previously focused on simple ovulation induction or oral contraceptive prescriptions. A multidisciplinary integrated care system involving endocrinology and obstetrics and gynecology is rapidly taking root to early prevention of the onset of cardiovascular disease and Type 2 diabetes.

Overcoming the Limits of Off-label Prescriptions with the Arrival of Obesity/Diabetes Blockbuster Drugs

The therapeutics market has long relied on off-label drugs, such as Metformin or Combined Oral Contraceptives (COC), due to the lack of FDA-approved dedicated treatments. However, as the metabolic nature of the disease has come to the fore, incretin-class GLP-1 receptor agonists in Phase 3 clinical trials, such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, are rapidly emerging as key alternatives to standard treatment. As clinical evidence accumulates that weight loss and improved insulin sensitivity restore ovulation rates, the label expansion strategies of major pharmaceutical companies are gaining momentum.

Developing Next-Generation Targeted Pipelines and Driving Biotech Growth

Global biotechs are accelerating clinical trials for innovative first-in-class pipelines that target not only metabolic abnormalities but also neuroendocrine and adrenal pathways. Spruce Biosciences is conducting a Phase 2 clinical trial of Tildacerfont, a corticotropin-releasing factor receptor-1 (CRF1) antagonist targeting adrenal hyperandrogenism, while May Health is progressing a Phase 3 clinical trial for an innovative medical device that replaces invasive surgery through ovarian re-balancing radiofrequency ablation. is important. The change in disease nomenclature is facilitating the establishment of clear clinical endpoints by the US FDA and European EMA, significantly expanding capital attraction and strategic licensing opportunities across the biotech venture ecosystem.